Paying for Medical Weight Loss: Insurance, Medicare, HSA and FSA

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 19, 2026 · Updated October 19, 2026 · 9 min read

Key takeaways

• Medicare Part D excludes agents used for weight loss, even for obesity, under section 1927(d)(2) of the Social Security Act as described in the CMS manual ^[4].
• The Medicare GLP-1 Bridge started July 1, 2026 and runs through December 31, 2027; adults need a BMI of 35 or higher, or a lower BMI plus a listed condition ^[1][2].
• KFF reported that 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in 2025 ^[6].
• In 2025, 43% of employers with 5,000 or more workers covered GLP-1s for weight loss, compared with 16% of firms with 200 to 999 workers ^[10].
• The IRS allows weight-loss program costs as medical expenses only when the program treats a specific disease diagnosed by a physician, such as obesity ^[11].

Does Medicare cover weight-loss medications?

Not through the regular Part D benefit, because federal law excludes them. The CMS Prescription Drug Benefit Manual lists, among drugs excluded under section 1927(d)(2) of the Social Security Act, "agents when used for anorexia, weight loss, or weight gain," and says the exclusion applies even when the purpose is not cosmetic, such as morbid obesity ^[4].

KFF explains the practical effect: Part D plans can cover GLP-1 medications only for FDA-approved uses other than obesity, such as type 2 diabetes. Medicaid works differently, because states decide whether to cover weight-loss drugs ^[6].

Original Medicare Part B does cover behavioral therapy for obesity if your BMI is 30 or higher. It includes a BMI screening and counseling sessions with a dietary assessment, and the counseling must come from a primary care provider in a primary care setting ^[5].

Medicare.gov says a person who already has a GLP-1 medicine covered by a Part D plan, such as for type 2 diabetes, is not eligible for the Bridge program described next, and that plans might cover GLP-1s for conditions such as type 2 diabetes, moderate to severe sleep apnea or fatty liver disease ^[2].

What is the Medicare GLP-1 Bridge, and who qualifies?

The Bridge is a temporary CMS demonstration that lets eligible Part D enrollees get certain GLP-1 drugs for a flat monthly copayment, from July 1, 2026 through December 31, 2027 ^[1]. CMS says it operates outside the Part D benefit: Part D sponsors do not bear financial risk, the Part D deductible does not apply, the copayment does not count toward out-of-pocket costs, and low-income subsidies are not provided ^[1].

Medicare.gov lists the covered products as Foundayo (tablet), Wegovy (injection or tablet) and the Zepbound KwikPen only; single-dose Zepbound vials and pens are not covered ^[2]. Eligibility requires age 18 or older and one of these at the start of therapy ^[2]:

• BMI of 35 or higher, or
• BMI of 30 or higher plus diastolic heart failure, uncontrolled high blood pressure or chronic kidney disease stage 3a or higher, or
• BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

The prescriber sends the prescription to the pharmacy and completes a prior authorization when requested, certifying that the drug is used as part of a lifestyle program focused on diet and exercise. Approval lasts through December 31, 2027, including refills and dose changes, unless the person switches GLP-1s ^[2].

The longer-term plan is less settled. CMS's BALANCE Model is a voluntary program in which CMS negotiates with manufacturers; CMS says it is not expected to launch in Medicare in 2027 and that the Bridge was extended to gather utilization data ahead of potential implementation in Part D ^[3]. Rules could change, so check Medicare.gov or call 1-800-MEDICARE for the current status ^[1][2].

Does Medicaid cover weight-loss medications in Florida and Colorado?

Coverage varies by state, and the state documents we reviewed list weight-loss drugs as not covered in both Florida and Colorado. KFF reported that 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in 2025 ^[6].

Colorado: the Health First Colorado pharmacy page lists "Weight-Loss Drugs" among categories of medications the program does not cover for any reason ^[7].

Florida: a 2024 Florida administrative final order quotes the Florida Medicaid Prescribed Drug Services Coverage Policy (December 2017), which lists "weight control medications" under specific non-covered criteria ^[9]. We could not confirm from the Agency for Health Care Administration pages we reviewed whether that has changed since.

There is a federal development to watch. Under BALANCE, state Medicaid agencies could join from May 2026 through January 1, 2027, and Medicaid beneficiaries receiving GLP-1s for weight management would get a manufacturer-provided lifestyle support program at no cost ^[3]. Participation is voluntary ^[3]. KFF's May 2026 review named no participating states, and the state application deadline was July 31, 2026 ^[6]. We did not find a published list showing Florida or Colorado participating, so ask your Medicaid plan directly.

What about employer and individual health plans?

Employer coverage of GLP-1s for weight loss exists but is far from universal, and it rises with company size. KFF's 2025 survey of employers found that 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999 workers and 43% of firms with 5,000 or more workers covered GLP-1s for weight loss ^[10].

Among firms that cover them, 34% require employees to meet with a dietitian, case manager or therapist, or join a lifestyle program, to get coverage. Of firms with 200 or more workers that did not cover GLP-1s, 67% said they were not likely to start within 12 months ^[10].

Colorado has a new state law. SB25-048, signed June 3, 2025, takes effect January 1, 2027. It requires large group plans offered in Colorado to cover treatment for obesity and pre-diabetes, including intensive behavioral or lifestyle therapy, medical nutrition therapy and metabolic and bariatric surgery. Carriers must also offer the policyholder the option to purchase coverage for FDA-approved anti-obesity medications, including at least one GLP-1 ^[8]. Whether your specific plan is subject to the law is a question for your benefits office.

Plans differ on whether they cover medications at all, which products, and what you must document first. Before assuming anything, ask the plan: is anti-obesity medication covered, is prior authorization required, is a lifestyle program or visit requirement attached, and what are the copay and any annual limit?

Can I use an HSA or FSA for medical weight loss?

Sometimes, if the treatment is for a disease diagnosed by a physician. IRS Publication 502 says you can include amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician, and gives obesity, hypertension or heart disease as examples ^[11]. HSA qualified medical expenses are amounts paid for medical care as defined in section 213(d) of the tax code, to the extent not reimbursed by insurance ^[12].

• Not included: gym, health club or spa dues, though separate fees for weight-loss activities there can be included. Diet food and beverages generally do not qualify either ^[11].
• Documentation: Pub 502 hinges on a physician's diagnosis ^[11]. For health FSAs, the IRS says you must give the plan a written statement from an independent third party showing the expense was incurred, and that it was not reimbursed by other coverage ^[12]. Ask your plan administrator whether it also wants a physician's letter of medical necessity.
• Eligibility for an HSA: you must be covered by a high-deductible health plan, and you cannot be enrolled in Medicare ^[12].
• Tax deduction: if you itemize, only medical expenses above 7.5% of adjusted gross income are deductible ^[11].

Rules for specific products, such as medications or supplements, can differ, and plan administrators apply their own reviews. This is general information, not tax advice; a tax professional can confirm how it applies to you.

What are manufacturer savings programs and cash-pay channels?

Manufacturers run programs for brand-name medicines, and eligibility rules turn on the kind of insurance you have. According to Lilly, the Zepbound savings card is for people with commercial insurance and excludes anyone enrolled in a government-funded program such as Medicare or Medicaid. Lilly also describes self-pay options for cash-paying patients. The page says program terms may change and the savings card terms expire December 31, 2026 ^[13].

According to Novo Nordisk, its Wegovy savings program is for people using commercial insurance or paying themselves. Government-insured patients may use it only if they self-pay and process the claim outside their insurance, and those purchases do not count toward a deductible or out-of-pocket maximum. The company reserves the right to modify or cancel the program at any time ^[14].

These pages describe manufacturer programs. Nothing here implies that Healthy Weight Loss 4 U offers a discount or takes part in any program. Terms change, so read the current terms before relying on any program.

Be careful with cheaper-looking alternatives. The FDA states that compounded drugs are not FDA approved and that the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. It advises getting a prescription from a doctor and filling it at a state-licensed pharmacy ^[15]. Our article on brand-name versus compounded GLP-1 drugs covers the distinction in more detail.

What should I know about medical credit cards and financing?

Medical financing products can spread out a payment, but they carry terms you must read first. The Consumer Financial Protection Bureau's 2023 report found that with deferred-interest healthcare cards, a borrower who has not paid the full balance by the end of the promotional period owes interest on the full purchase amount, not just the remaining balance ^[16].

The report found that about 20% of healthcare deferred-interest purchases from 2015 to 2020 were charged deferred interest, that promotional periods ranged from 6 to 18 months, and that the typical medical credit card APR was 26.99%, compared with a mean of about 16% for general-purpose credit cards ^[16]. That is 2023 data about the category, not about any specific card, including CareCredit-type products.

Before signing, confirm the APR, whether interest is deferred or waived, the promotional period length, the minimum payment and any fees. Ask whether you could pay the balance within the promotional period.

What this means in practice

• Start by asking your plan whether anti-obesity medication is covered, and request the criteria in writing. Employer coverage varies widely by firm size ^[10].
• If you are on Medicare, check Medicare.gov for the GLP-1 Bridge; eligibility depends on BMI, listed conditions and the specific products, and approval is currently valid through December 31, 2027 ^[2].
• If you are on Medicaid in Florida or Colorado, ask your plan directly. The state documents we reviewed list weight-loss drugs as not covered, and BALANCE participation is voluntary for states ^[3][7][9].
• In Colorado, ask your employer whether its large group plan is changing on January 1, 2027 under SB25-048 ^[8].
• For HSA or FSA spending, get the diagnosis documented, keep itemized receipts and ask your plan administrator what it requires ^[11][12].
• Treat manufacturer savings terms as changing, and confirm eligibility against your insurance type before relying on them ^[13][14].
• Read every term of any financing agreement, especially deferred interest, APR and the promotional period ^[16].

When to talk to a clinician

Talk with a licensed clinician before you plan your finances around a treatment, because coverage rules often depend on a documented diagnosis, BMI and related conditions. A clinician can document your medical history and explain whether a particular treatment may be appropriate, which is often what a plan or the IRS asks for.

At Healthy Weight Loss 4 U, every program begins with a clinician evaluation, and that evaluation is the right place to raise insurance, Medicare, HSA, FSA or financing questions. We cannot promise coverage or reimbursement, and the plan or program makes the final decision.

Frequently asked questions

Sources

1. Medicare GLP-1 Bridge. Centers for Medicare & Medicaid Services, 2026. www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
2. Medicare GLP-1 Bridge: eligibility, covered drugs and how to get coverage. Medicare.gov (CMS), 2026. www.medicare.gov/glp1bridge
3. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. CMS Innovation Center, 2026. www.cms.gov/priorities/innovation/innovation-models/balance
4. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Centers for Medicare & Medicaid Services, 2016. www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/chapter-6-part-d-drugs-and-formulary-requirements-v011916.pdf
5. Obesity behavioral therapy. Medicare.gov (CMS), 2026. www.medicare.gov/coverage/obesity-behavioral-therapy
6. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. KFF, 2026. www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
7. Health First Colorado Pharmacy Benefits. Colorado Department of Health Care Policy and Financing, 2026. hcpf.colorado.gov/pharmacy-benefits
8. SB25-048 Diabetes Prevention and Obesity Treatment Act. Colorado General Assembly, 2025. leg.colorado.gov/bills/sb25-048
9. Final Order, AHCA Case No. 24-FH0081 (quoting Florida Medicaid Prescribed Drug Services Coverage Policy, Dec. 2017, Section 5.2). Florida Agency for Health Care Administration, via Florida Health Justice Project library, 2024. library.floridahealthjustice.org/24-fh0081-final-order_pdf/
10. 2025 Employer Health Benefits Survey. KFF, 2025. www.kff.org/health-costs/2025-employer-health-benefits-survey/
11. Publication 502: Medical and Dental Expenses (2025). Internal Revenue Service, 2025. www.irs.gov/publications/p502
12. Publication 969: Health Savings Accounts and Other Tax-Favored Health Plans (2025). Internal Revenue Service, 2025. www.irs.gov/publications/p969
13. Zepbound savings and insurance options. Eli Lilly and Company, 2026. zepbound.lilly.com/savings
14. Savings Offer Program for Wegovy (semaglutide). Novo Nordisk (NovoCare), 2026. www.novocare.com/patient/medicines/wegovy/savings-offer.html
15. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2024. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
16. Medical Credit Cards and Financing Plans. Consumer Financial Protection Bureau, 2023. files.consumerfinance.gov/f/documents/cfpb_medical-credit-cards-and-financing-plans_2023-05.pdf

Keep reading